Table 2.
Treatment details of patients in the PHOTOSTENT-02 trial
| PDT+stenting | Stenting alone | P values | |
| n=46 N (%) |
n=46 N (%) |
||
| Time from randomisation to PDT (days)* | 9 (5–12) | NA | |
| Patient underwent repeat biliary stenting | |||
| No | 27 (59) | 21 (46) | 0.21 |
| Yes | 19 (41) | 25 (54) | |
| Number of separate restenting procedures | |||
| 1 | 9 (47) | 11 (44) | 0.55 |
| 2 | 6 (32) | 6 (24) | |
| >3 | 4 (22) | 8 (32) | |
| Time from randomisation to first restenting procedure (days)* | 96 (74–139) | 69 (46–134) | 0.29 |
| Additional treatments received | |||
| Received chemotherapy | 13 (28) | 24 (52) | 0.019 |
| Of which: | |||
| Gemcitabine | 3 | 8 | |
| Gemcitabine+cisplatin | 6 | 12 | |
| Other chemotherapy regimen | 4 | 4 | |
| Time from randomisation until starting chemotherapy (days)* | 135 (65–297) | 43 (29–106) | 0.005 |
| Other additional treatment | 5 (11) | 14 (30) | 0.02 |
| Of which: | |||
| Radiotherapy | 2 | 3 | |
| Other † | 3 | 11 |
*Median (IQR). The Mann-Whitney U test was used to compare median time to event for only those patients who underwent repeat biliary stenting or received chemotherapy.
†Stent alone (11 patients, 14 records): ERCP (2); percutaneous transhepatic drainage (1); cancer bowel operation (1); percutaneous drainage of ruptured liver abscess (1); ascites drainage (1); palliative care (1); palliative gastrojejeunostomy (1); HDAC inhibitor (1); catheter inserted (1); nutritional support (1); antibiotics for cholangitis (1); bile acid sequestrant (1); antibiotics for chest infection (1). PDT (3 patients, 3 records): peritoneum transhepatic stent (1); palliative care (1); gentamycin and oral ciprofloxacin for sepsis (1).
ERCP, endoscopic retrograde cholangiopancreatography; HDAC, histone deacetylase; PDT, photodynamic therapy.